Overview

This trial is active, not recruiting.

Condition hiv infections
Treatments ritonavir, amprenavir
Sponsor Gathe, Joseph, M.D.
Trial identifier NCT00006591, 313A, APV-430

Summary

The purpose of this study is to determine if treatment with an anti-HIV drug containing ritonavir and Agenerase is safe and can lower the level of HIV in the blood in patients who have failed an anti-HIV drug treatment containing nelfinavir.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification safety study
Primary purpose treatment

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria Patients may be eligible for this study if they: - Are 18 years of age or older. - Are HIV-positive. - Have a viral load (level of HIV in the body) of more than 1,000 copies/ml. - Have had more than 12 weeks of prior anti-HIV drug treatment. - Have failed a previous anti-HIV treatment containing nelfinavir as the only protease inhibitor. - Are responsive to Agenerase. - Are able to follow study requirements. Exclusion Criteria Patients will not be eligible for this study if they: - Are intolerant to ritonavir (an anti-HIV drug). - Have or have had problems with absorption. - Have liver disease or damage. - Have pancreatic disease or damage. - Have taken any protease inhibitor other than nelfinavir. - Are receiving investigational drugs or devices from another study. - Are pregnant or breast-feeding. - Currently use triazolam, astemizole, ergot medications, cisapride, midazolam, bepridil, rifampin, terfenadine, or pimozide. - Have a bleeding disorder. - Have previously been treated with Agenerase. - Are receiving nonnucleosides.

Additional Information

Official title The Safety and Efficacy of a Ritonavir-Enhanced Agenerase Regimen as Salvage Therapy in HIV-Infected Individuals
Description HIV-infected patients will be treated with a ritonavir-enhanced Agenerase regimen.
Trial information was received from ClinicalTrials.gov and was last updated in June 2005.
Information provided to ClinicalTrials.gov by NIH AIDS Clinical Trials Information Service.